drugset / Trial / NCT00238966

Extension Study to Assess Tolerability and Safety of Enteric-coated Mycophenolate Sodium in Renal Transplant Recipients Who Received Mycophenolate Mofetil

NCT00238966

Phase 4 Completed 187 enrolled Novartis
Non-randomizedSingle-groupOpen-labelPrevention

Summary

This extension study is considered to allow patients being treated with EC-MPS to collect further information on the long-term safety of this drug.

Timeline

Start
2002-11
Primary completion
2005-04
Completion
2005-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Mycophenolate Sodium Unknown

Indications

No indication recorded.